HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Missy McKean-Matthews Selected Research

Ustekinumab (CNTO 1275)

2/2022Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Missy McKean-Matthews Research Topics

Disease

8Psoriasis (Pustulosis Palmaris et Plantaris)
04/2024 - 08/2018
1Psoriatic Arthritis
04/2022
1Pain (Aches)
04/2021

Drug/Important Bio-Agent (IBA)

8ixekizumabIBA
04/2024 - 08/2018
3Interleukin-17 (Interleukin 17)IBA
04/2024 - 08/2018
2Monoclonal AntibodiesIBA
04/2024 - 08/2021
1Ustekinumab (CNTO 1275)FDA Link
02/2022
1Etanercept (Enbrel)FDA Link
08/2021
1CytokinesIBA
08/2018

Therapy/Procedure

2Therapeutics
04/2024 - 02/2022